MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/vaccines14020121

Медицинская библиотека · Vaccines · 2026

Dose-Dependent Efficacy of a Riboflavin and Ultraviolet Light-Inactivated Whole-Virion SARS-CoV-2 Vaccine in a Hamster Infection Challenge Model.

Altina Noelia, Ragan Izabela K, Arnett Kimberly A, Jones Socks, Glass Arielle, Dutt Taru S, Obregon-Henao Andres, Maldonado Pablo, Harris Mac, Bowen Richard A, Kruh-Garcia Nicole, Heaslip Darragh, Yonemura Susan, Henao-Tamayo Marcela, Goodrich Raymond P

СтатьяПеревод пока не подготовлен

Аннотация

Background

A novel platform to produce whole-virion vaccines using riboflavin and ultraviolet (UV) light for photochemical inactivation has been developed. We previously reported on the potential for this platform to produce a safe and effective inactivated whole-virion SARS-CoV-2 vaccine. Feasibility studies used a hamster infection challenge model to explore the effects of route of administration and adjuvants on immune responses elicited by the vaccine candidate. Here, we utilized the same animal model to evaluate the dose response to the vaccine candidate in combination with the adjuvant CpG1018.

Methods

A pilot batch of the vaccine candidate was produced at a contract development and manufacturing organization (CDMO) for use in this study. A two-dose intramuscular regimen at three antigen concentrations formulated with CpG1018 adjuvant was assessed against a live SARS-CoV-2 (USA-WA-1/2020) challenge.

Results

The vaccine elicited dose-dependent neutralizing antibody responses, with peak PRNT50 titers exceeding 1:5120. Vaccination significantly reduced lung viral burden and mitigated pulmonary pathology compared to controls. Antibodies persisted up to 154 days post-vaccination and neutralized Delta and Omicron (Jn.1) variants but showed limited activity against XBB.1.5. Flow cytometry revealed enhanced CD4+ Th1-biased responses in higher-dose groups.

Conclusions

These findings demonstrate the protective efficacy of the SolaVAX SARS-CoV-2 vaccine candidate and support further evaluation of this vaccine production platform.

Для цитирования: Altina Noelia, Ragan Izabela K, Arnett Kimberly A, Jones Socks, Glass Arielle, Dutt Taru S, Obregon-Henao Andres, Maldonado Pablo, Harris Mac, Bowen Richard A, Kruh-Garcia Nicole, Heaslip Darragh, Yonemura Susan, Henao-Tamayo Marcela, Goodrich Raymond P. Dose-Dependent Efficacy of a Riboflavin and Ultraviolet Light-Inactivated Whole-Virion SARS-CoV-2 Vaccine in a Hamster Infection Challenge Model.. Vaccines. 2026. DOI: 10.3390/vaccines14020121.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.